Testing for MSI/MMR status at diagnosis; a key for the 1L treatment of eligible patients with advanced CRC

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Length: 06:21

A short video detailing the testing data on KEYNOTE-177, which highlights how determining MSI/MMR status is an important step for your patients with advanced CRC and can help identify potential eligibility for KEYTRUDA® (pembrolizumab).

More information about KEYTRUDA® (pembrolizumab) in metastatic CRC

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website